Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
Cancer J. 2024 Mar-Apr 01;30(2):54-70. doi: 10.1097/PPO.0000000000000706.ABSTRACTPatients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-ly...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Ahmad A Tarhini Ella Castellano Islam Eljilany Source Type: research
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features
We present a 35-year female with lung cancer with choriocarcinoma features. Her disease involved the right lower lung, brain, and thoracic lymph nodes. The pathology from brain metastasis was reported as “metastatic choriocarcinoma” (a germ cell tumor) by local pathologists. She initiated carboplatin and etoposide, a regimen for choriocarcinoma. Subsequently, her case was assessed by pathologists from an academic cancer center, who gave the diagnosis of “adenocarcinoma with aberrant expression of β-hCG” and finally pathologists at our hospital, who gave the diagnosis of “poorly differentiated carcinoma with chor...
Source: Frontiers in Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin
AbstractImmune checkpoint inhibitors (ICIs) exhibit remarkable antitumor activity and immune-related cardiotoxicity of unknown pathomechanism. The aim of the study was to investigate the ICI class-dependent cardiotoxicity in vitro and pembrolizumab ’s (Pem’s) cardiotoxicity in vivo, seeking for translational prevention means. Cytotoxicity was investigated in primary cardiomyocytes and splenocytes, incubated with ipilimumab, Pem and avelumab. Pem’s cross-reactivity was assessed by circular dichroism (CD) on biotechnologically produced hum an and murine PD-1 and in silico. C57BL6/J male mice received IgG4 or Pem for 2 ...
Source: Basic Research in Cardiology - March 23, 2024 Category: Cardiology Source Type: research
Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis
CONCLUSION: The analysis focused on the probability of irAEs occurrence in each system when mRCC patients were treated with different ICI-based therapies, potentially offering significant value for guiding clinical prevention, early diagnosis, and management of irAEs. The limitations of the study included the potential heterogeneity and low certainty of part of the evidence.PMID:38518592 | DOI:10.1016/j.intimp.2024.111884 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 22, 2024 Category: Allergy & Immunology Authors: Shan Wang Hongwei Lv Jing Yu Miao Chen Source Type: research
Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis
CONCLUSION: The analysis focused on the probability of irAEs occurrence in each system when mRCC patients were treated with different ICI-based therapies, potentially offering significant value for guiding clinical prevention, early diagnosis, and management of irAEs. The limitations of the study included the potential heterogeneity and low certainty of part of the evidence.PMID:38518592 | DOI:10.1016/j.intimp.2024.111884 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 22, 2024 Category: Allergy & Immunology Authors: Shan Wang Hongwei Lv Jing Yu Miao Chen Source Type: research
Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management
Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical teams. Indeed, neurological irAEs are potentially severe and their diagnosis require prompt recognition and treatment. Additionally, the spectrum of neurological irAEs is broad, affecting either neuromuscular junction, peripheral or central nervous system. Here, we described the case of a 55-year man with metastatic melanoma, facing a brutal right peripheral cerebral palsy after his third ipilimumab/nivolumab infusion. After the case presentati...
Source: Frontiers in Immunology - March 22, 2024 Category: Allergy & Immunology Source Type: research
Cancers, Vol. 16, Pages 1247: Neo-Adjuvant Therapy for Metastatic Melanoma
ooi
Melanoma treatment is leading the neo-adjuvant systemic (NAS) therapy field. It is hypothesized that having the entire tumor in situ, with all of the heterogeneous tumor antigens, allows the patient’s immune system to have a broader response to the tumor in all its shapes and forms. This translates into a higher clinical efficacy. Another benefit of NAS therapy potentially includes identifying patients who have a favorable response, which could offer an opportunity for the de-escalation of the extent of surgery and the need for adjuvant radiotherapy and/or adjuvant systemic therapy, as well as tailori...
Source: Cancers - March 22, 2024 Category: Cancer & Oncology Authors: Anke M. J. Kuijpers Alexander C. J. van Akkooi Tags: Review Source Type: research
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
CONCLUSIONS: RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.PMID:38504270 | DOI:10.1186/s13046-024-02984-2 (Source: Cell Research)
Source: Cell Research - March 20, 2024 Category: Cytology Authors: Christopher Montemagno Arnaud Jacquel Charlotte Pandiani Olivia Rastoin Rosie Dawaliby Thomas Schmitt Maxence Bourgoin H éliciane Palenzuela Anne-Laure Rossi Damien Ambrosetti Jerome Durivault Frederic Luciano Delphine Borchiellini Julie Le Du Leticia Ch Source Type: research
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored t... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - March 19, 2024 Category: Cancer & Oncology Authors: Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, H éliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Tags: Research Source Type: research
Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma
CONCLUSIONS: Our results suggest that post-nephrectomy RCC patients with sarcomatoid differentiation and high PD-L1 expression were more responsive to ICIs. Furthermore, pembrolizumab monotherapy exhibited superior DFS and OS results over other adjuvant therapies.PMID:38494564 | DOI:10.1245/s10434-024-15121-2 (Source: Ann Oncol)
Source: Ann Oncol - March 18, 2024 Category: Cancer & Oncology Authors: Kaiyue Ding Zhixuan Yang Danyan Zhang Lin Sun Source Type: research
Selective activation of IFN γ-ipilimumab enhances the therapeutic effect and safety of ipilimumab
CONCLUSION: IFNγ-ipilimumab improved the effectiveness of ipilimumab while reducing its side effects. It is likely that future immunotherapies would rely on such antibodies to activate local cancer cells or immune cells, thereby increasing the therapeutic effectiveness of cancer treatments and ensuring their safety.PMID:38493818 | DOI:10.1016/j.ijbiomac.2024.130945 (Source: International Journal of Biological Macromolecules)
Source: International Journal of Biological Macromolecules - March 17, 2024 Category: Biochemistry Authors: Yi-Jung Huang Kai-Wen Ho Tian-Lu Cheng Yen-Tseng Wang Shi-Wei Chao Bo-Cheng Huang Yu-Shu Chao Chia-Yu Lin Yun-Han Hsu Fang-Ming Chen Chih-Hung Chuang Source Type: research
Selective activation of IFN γ-ipilimumab enhances the therapeutic effect and safety of ipilimumab
CONCLUSION: IFNγ-ipilimumab improved the effectiveness of ipilimumab while reducing its side effects. It is likely that future immunotherapies would rely on such antibodies to activate local cancer cells or immune cells, thereby increasing the therapeutic effectiveness of cancer treatments and ensuring their safety.PMID:38493818 | DOI:10.1016/j.ijbiomac.2024.130945 (Source: International Journal of Biological Macromolecules)
Source: International Journal of Biological Macromolecules - March 17, 2024 Category: Biochemistry Authors: Yi-Jung Huang Kai-Wen Ho Tian-Lu Cheng Yen-Tseng Wang Shi-Wei Chao Bo-Cheng Huang Yu-Shu Chao Chia-Yu Lin Yun-Han Hsu Fang-Ming Chen Chih-Hung Chuang Source Type: research
